Figure 4.

Drug development strategy targeting type II and III TA system. (a) Type II TA system. The peptide that binds to toxin inhibits the interaction with antitoxin protein.; (b) Type III TA system. The RNA oligomer that binds to the RNA antitoxin or peptide that binds to the toxin prohibiting the interaction with RNA antitoxin inhibits the toxin protein binding to RNA antitoxin. The active toxin proteins of both TA system bind to the mRNA and cleavage it resulting in cell death. Toxin and antitoxin are defined as blue and red colors, respectively.